Treatment of obesity in US children and adolescents before and after the AAP guidelines

Patricia J Rodriguez,Duy Do,Samuel Gratzl,Brianna M Goodwin Cartwright,Nicholas Stucky,Davene R Wright
DOI: https://doi.org/10.1101/2024.10.25.24316147
2024-10-28
Abstract:Importance: The American Academy of Pediatrics (AAP) published new comprehensive guidelines for childhood obesity treatment, including pharmacotherapy. However, changes in treatment patterns following these guidelines remain unknown. Objective: To assess changes in childhood and adolescent obesity treatment following the new AAP guidelines. Design: Using Truveta electronic health record (EHR) data, this cohort study analyzed outpatient visits between January 2021 and June 2024 for children (age 8-11) and adolescents (age 12-17) with obesity and no evidence of type 2 diabetes (T2D). For patients with multiple visits, one visit was randomly selected. Patients without a recent history of specific obesity treatments were followed for evidence of obesity treatment at or following their visit, including nutrition referral within 14 days or nutrition counseling within 90 days, and, separately, pharmacotherapy prescriptions for weight management (on- or off-label) within 14 days. Interrupted time series models were used to compare differences in nutrition counseling or referral and pharmacotherapy before versus after the AAP guidelines were released. Setting: Clinical and prescribing data from EHRs from a collective of US health systems. Participants: 329,357 patients aged 8 to 17 with an outpatient office visit, a BMI percentile indicating obesity, and no T2D diagnosis. Exposure: Release of the AAP guidelines in January 2023. Main Outcomes and Measures: Evidence of obesity treatment at or following the eligible visit with (1) nutrition referral or counseling, and (2) pharmacotherapy. Results: The study population of 329,581 patients included 120,734 (36.6%) children and 208,847 (63.4%) adolescents. The mean (SD) BMI percentile was 97.4 (1.6), with 119,864 (36.4%) having severe obesity (class 2 or 3). Overall, a minority of patients without a recent history of obesity treatment had evidence of nutrition referral or counseling (4.0%) or pharmacotherapy (0.4%) during or shortly after their visit. Following the AAP guidelines, indicators of both immediate (odds ratio [95% CI]: 1.38 [1.08-1.75]) and gradual monthly changes (1.06 [1.04-1.08]) were observed for pharmacotherapy use. An immediate change in nutrition counseling and referral was observed following guidelines (1.34 [1.24-1.45]), but no additional gradual monthly changes were observed (1.0 [0.99-1.01]). Conclusions and Relevance: While nutrition counseling or referral and pharmacotherapy use increased, overall rates of obesity treatment remained low.
Pediatrics
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to evaluate whether the obesity treatment patterns for children and adolescents in the United States have changed after the American Academy of Pediatrics (AAP) released new comprehensive obesity treatment guidelines in January 2023. Specifically, the study focused on the changes in the use of nutrition counseling or referrals and drug treatment before and after the release of the guidelines. ### Research Background - **Obesity Problem**: In the United States, approximately 20% of adolescents suffer from obesity, which is associated with increased short - and long - term health risks such as cardiovascular diseases, type 2 diabetes, hypertension, dyslipidemia, and mental health problems. - **AAP Guidelines**: In January 2023, the AAP released its first recommendations on the assessment and treatment of obesity in children and adolescents, emphasizing the importance of early, evidence - based treatment. The first - line intervention recommended in the guidelines is high - intensity health behavior and lifestyle treatment (IHBLT), and for adolescents aged 12 and above, drug treatment is also recommended as a supplement to IHBLT. ### Research Objectives - **Evaluate Changes**: The study aims to evaluate the changes in the obesity treatment patterns for children and adolescents before and after the release of the AAP guidelines, especially the use of nutrition counseling or referrals and drug treatment. ### Research Design - **Data Source**: Use Truveta electronic health record (EHR) data to analyze outpatient visit records from January 2021 to June 2024. - **Research Subjects**: Children and adolescents aged 8 to 17, whose BMI percentiles meet the obesity criteria and have no type 2 diabetes diagnosis. - **Exposure Factor**: The release date of the AAP guidelines was January 7, 2023. - **Primary Outcome Measures**: - Nutrition Counseling or Referral: There is a record of referral to a dietitian within 14 days after the visit, or a record of nutrition counseling within 90 days. - Drug Treatment: A prescription for drugs used for weight management (including on - label and off - label use) is issued within 14 days after the visit. ### Main Results - **Overall Low Treatment Rate**: Although the utilization rates of nutrition counseling or referral and drug treatment have increased after the release of the AAP guidelines, the overall treatment rate is still low. - **Immediate Changes**: - Nutrition Counseling or Referral: It increased immediately by 34% after the release of the guidelines (OR: 1.34 [95% CI: 1.24 - 1.45]). - Drug Treatment: It increased immediately by 38% after the release of the guidelines (OR: 1.38 [95% CI: 1.08 - 1.75]). - **Gradual Changes**: - Nutrition Counseling or Referral: The monthly change is not significant (OR: 1.0 [95% CI: 0.99 - 1.01]). - Drug Treatment: It gradually increases by 6% per month (OR: 1.06 [95% CI: 1.04 - 1.08]). ### Conclusions - **Low Treatment Rate**: Although the utilization rates of nutrition counseling or referral and drug treatment have increased after the release of the AAP guidelines, the overall treatment rate is still low. - **Future Research Directions**: Further research is needed on the preferences of doctors and families for obesity treatment options, and how to balance the time, cost, safety, uncertainty, and their short - and long - term effects of treatment. In addition, the accessibility of these treatments needs to be improved, and the obesity treatment of children and adolescents needs to be continuously monitored. Through these research results, the author hopes to provide valuable references for future clinical practice and policy - making.